This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Prostaglandin (PG) D2 is a major prostanoid produced in the CNS of various mammals including humans and acts as an
endogeneous sleep-promoting substance and an inflammatory lipid mediator. PGD2 is produced by two distinct synthases,
i.e., lipocalin-type PGD synthase (L-PGDS) and hematopoietic PGD synthase (H-PGDS), and stimulates two distinct G-proteincoupled
receptors, Gs-coupled DP1 receptor and Gi-coupled DP2 (CRTH-2/GPR-44) receptor. (1) In the CNS, L-PGDS is
dominantly expressed in the leptomeninges, choroid plexus and oligodendrocytes, and secreted into the cerebrospinal fluid
(CSF) as beta-trace protein, a major human CSF protein, whereas H-PGDS is localized in microglia and mast cells. DP1
receptor is localized in subpopulation of cells within the leptoneninges and glial limitance and upregulated in hypertrophied
astrocytes in various neuro-inflammatory circumstances. DP2 receptor is expressed in various inflammatory cells including
activated microglia and invaded macrophages after brain damages. By using gene-knockout mice and pharmacological
blockades with enzyme inhibitors or receptor antagonists, we revealed that the L-PGDS/DP1 receptor system is involved
in the regulation of sleep; (2) the L-PGDS/DP2 system, in myelination of Schwann cells; (3) the H-PGDS/DP1 system, in the
suppression of epilepsy; (4) and the H-PGDS/DP2 system, in the chemotaxis of inflammatory cells during neuroinflammation.
We reported that L-PGDS/beta-trace protein secreted into the human CSF is upregulated after subarachnoid hemorrhage and
acts as a scavenger for biliverdin, a harmful heme-degrading product.(5) We recently found that L-PGDS/beta-trace protein
binds PGD2 at a high affinity with Kd value in a submicromoler range and also covalently binds PGJ2 derivatives, nonenzymic
dehydration products of PGD2. These results are useful to develop new drugs targeting the PGD2 system and diagnostic kits for
various neuroinflammatory and neuroimmunological diseases.
Yoshihiro Urade has completed his PhD at the age of 29 years from Kyoto University in 1983 and postdoctoral studies from ERATO project of Japan Science and
Technology Agency. He was the visiting professor of Roche Institute of Molecular Biology in 1988, the senior scientist of International Laboratories of CIBA-GEIGY Japan
in 1990, and the vise-head of Department of Molecular Behavioral Biology of Osaka Bioscience Institute in 1993, and the head of this department in 1998 to 2014. In
2014, he became a principal investigator of a newly established institute in Tsukuba University. He has published more than 300 papers in reputed journals and has been
serving as an editorial board member of Prostaglandins, Leukotriens and Essential Fatty Acids and as the secretary general of Asian Society of Sleep Medicine (ASSM).
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals